M27-A2 Vol. 22 No. 15 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition

This document addresses the selection and preparation of antifungal agents; implementation and interpretation of test procedures; and quality control requirements for susceptibility testing of yeasts that cause invasive fungal infections.

A standard for global application developed through the NCCLS consensus process.



# NCCLS... Serving the World's Medical Science Community Through Voluntary Consensus

NCCLS is an international, interdisciplinary, nonprofit, standards-developing, and educational organization that promotes the development and use of voluntary consensus standards and guidelines within the healthcare community. It is recognized worldwide for the application of its unique consensus process in the development of standards and guidelines for patient testing and related healthcare issues. NCCLS is based on the principle that consensus is an effective and cost-effective way to improve patient testing and healthcare services.

In addition to developing and promoting the use of voluntary consensus standards and guidelines, NCCLS provides an open and unbiased forum to address critical issues affecting the quality of patient testing and health care.

#### PUBLICATIONS

An NCCLS document is published as a standard, guideline, or committee report.

**Standard** A document developed through the consensus process that clearly identifies specific, essential requirements for materials, methods, or practices for use in an unmodified form. A standard may, in addition, contain discretionary elements, which are clearly identified.

**Guideline** A document developed through the consensus process describing criteria for a general operating practice, procedure, or material for voluntary use. A guideline may be used as written or modified by the user to fit specific needs.

**Report** A document that has not been subjected to consensus review and is released by the Board of Directors.

#### **CONSENSUS PROCESS**

The NCCLS voluntary consensus process is a protocol establishing formal criteria for:

- the authorization of a project
- the development and open review of documents
- the revision of documents in response to comments by users
- the acceptance of a document as a consensus standard or guideline.

Most NCCLS documents are subject to two levels of consensus—"proposed" and "approved." Depending on

the need for field evaluation or data collection, documents may also be made available for review at an intermediate (i.e., "tentative") consensus level.

**Proposed** An NCCLS consensus document undergoes the first stage of review by the healthcare community as a proposed standard or guideline. The document should receive a wide and thorough technical review, including an overall review of its scope, approach, and utility, and a line-by-line review of its technical and editorial content.

**Tentative** A tentative standard or guideline is made available for review and comment only when a recommended method has a well-defined need for a field evaluation or when a recommended protocol requires that specific data be collected. It should be reviewed to ensure its utility.

**Approved** An approved standard or guideline has achieved consensus within the healthcare community. It should be reviewed to assess the utility of the final document, to ensure attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional consensus documents.

NCCLS standards and guidelines represent a consensus opinion on good practices and reflect the substantial agreement by materially affected, competent, and interested parties obtained by following NCCLS's established consensus procedures. Provisions in NCCLS standards and guidelines may be more or less stringent than applicable regulations. Consequently, conformance to this voluntary consensus document does not relieve the user of responsibility for compliance with applicable regulations.

#### COMMENTS

The comments of users are essential to the consensus process. Anyone may submit a comment, and all comments are addressed, according to the consensus process, by the NCCLS committee that wrote the document. All comments, including those that result in a change to the document when published at the next consensus level and those that do not result in a change, are responded to by the committee in an appendix to the document. Readers are strongly encouraged to comment in any form and at any time on any NCCLS document. Address comments to the NCCLS Executive Offices, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA.

#### **VOLUNTEER PARTICIPATION**

Healthcare professionals in all specialties are urged to volunteer for participation in NCCLS projects. Please contact the NCCLS Executive Offices for additional information on committee participation. Volume 22

M27-A2

# Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition

# Abstract

NCCLS document M27-A2—Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition describes a method for testing the susceptibility of antifungal agents to yeast that cause invasive fungal infections, including Candida species (and Candida glabrata), and Cryptococcus neoformans. Selection and preparation of antifungal agents, implementation and interpretation of test procedures, and the purpose and implementation of quality control procedures are discussed. A careful examination of the responsibilities of the manufacturer and the user in quality control is also presented.

NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition. NCCLS document M27-A2 (ISBN 1-56238-469-4). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.

THE NCCLS consensus process, which is the mechanism for moving a document through two or more levels of review by the healthcare community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of NCCLS documents. Current editions are listed in the *NCCLS Catalog*, which is distributed to member organizations, and to nonmembers on request. If your organization is not a member and would like to become one, and to request a copy of the *NCCLS Catalog*, contact the NCCLS Executive Offices. Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: exoffice@nccls.org; Website: www.nccls.org

Number 15

M27-A2 ISBN 1-56238-469-4 ISSN 0273-3099

# Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition

Volume 22 Number 15

Michael A. Pfaller, M.D., Chairholder Vishnu Chaturvedi, Ph.D. Ana Espinel-Ingroff, Ph.D. Mahmoud A. Ghannoum, M.Sc., Ph.D. Linda L. Gosey, M.T.(ASCP) Frank C. Odds, Ph.D., FRC Path. John H. Rex, M.D. Michael G. Rinaldi, Ph.D. Daniel J. Sheehan, Ph.D. Thomas J. Walsh, M.D. David W. Warnock, Ph.D., FRC Path.



Number 15

This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system, transmitted, or made available in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without prior written permission from NCCLS, except as stated below.

NCCLS hereby grants permission to reproduce limited portions of this publication for use in laboratory procedure manuals at a single site, for interlibrary loan, or for use in educational programs provided that multiple copies of such reproduction shall include the following notice, be distributed without charge, and, in no event, contain more than 20% of the document's text.

Reproduced with permission, from NCCLS publication M27-A2—*Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard*—*Second Edition* (ISBN 1-56238-469-4). Copies of the current edition may be obtained from NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Permission to reproduce or otherwise use the text of this document to an extent that exceeds the exemptions granted here or under the Copyright Law must be obtained from NCCLS by written request. To request such permission, address inquiries to the Executive Director, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.

Copyright <sup>©</sup>2002. The National Committee for Clinical Laboratory Standards.

#### **Suggested Citation**

(NCCLS. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition.* NCCLS document M27-A2 [ISBN 1-56238-469-4]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.)

**Proposed Standard** December 1992

**Tentative Standard** October 1995

**Approved Standard** June 1997

Approved Standard—Second Edition August 2002

ISBN 1-56238-469-4 ISSN 0273-3099

Volume 22	M2
Committee Membership	
Area Committee on Microbiology	
James H. Jorgensen, Ph.D. Chairholder	University of Texas Health Center San Antonio, Texas
Mary Jane Ferraro, Ph.D., M.P.H. Vice-Chairholder	Massachusetts General Hospital Boston, Massachusetts
Subcommittee on Antifungal Susceptibility	7 Tests
Michael A. Pfaller, M.D. Chairholder	University of Iowa College of Medicine Iowa City, Iowa
Vishnu Chaturvedi, Ph.D.	New York State Department of Health Albany, New York
Ana Espinel-Ingroff, M.S., Ph.D.	Medical College of Virginia/VCU Richmond, Virginia
Mahmoud A. Ghannoum, M.Sc., Ph.D.	Center for Medical Mycology, Case Western Reserve University, and University Hospitals of Cleveland Cleveland, Ohio
Linda L. Gosey, M.T.(ASCP)	Food and Drug Administration Rockville, Maryland
Frank C. Odds, Ph.D., FRC Path.	University of Aberdeen Scotland, United Kingdom
John H. Rex, M.D.	University of Texas Health Science Ctr. at Ho Houston, Texas
Michael G. Rinaldi, Ph.D.	University of Texas Health Science Center San Antonio, Texas
Daniel J. Sheehan, Ph.D.	Pfizer Inc. New York, New York
Thomas J. Walsh, M.D.	National Cancer Institute Bethesda, Maryland
David W. Warnock, Ph.D., FRC Path.	Centers for Disease Control and Prevention Atlanta, Georgia

Arthur L. Barry, Ph.D.

Clinical Microbiology Institute Wilsonville, Oregon

# Number 15

Lois M. Schmidt, D.A. *Staff Liaison* 

Tracy Ann Dooley, M.L.T.(ASCP) Project Manager

Patrice E. Polgar *Editor* 

Donna M. Wilhelm Assistant Editor NCCLS Wayne, Pennsylvania NCCLS

NCCLS Wayne, Pennsylvania

NCCLS Wayne, Pennsylvania

NCCLS Wayne, Pennsylvania

Volume 22

M27-A2

# Active Membership (as of 1 July 2002)

**Sustaining Members** 

Abbott Laboratories American Association for Clinical Chemistry Beckman Coulter, Inc. BD and Company bioMérieux, Inc. CLMA College of American Pathologists GlaxoSmithKline Nippon Becton Dickinson Co., Ltd. Ortho-Clinical Diagnostics, Inc. Pfizer Inc Roche Diagnostics, Inc.

#### **Professional Members**

AISAR-Associazione Italiana per lo Studio degli American Academy of Family Physicians American Association for **Clinical Chemistry** American Association for Respiratory Care American Chemical Society American Medical Technologists American Public Health Association American Society for Clinical Laboratory Science American Society of Hematology American Society for Microbiology American Type Culture Collection, Inc. Asociación Española Primera de Socorros (Uruguay) Asociacion Mexicana de Bioquimica Clinica A.C. Assn. of Public Health Laboratories Assoc. Micro. Clinici Italiani-A.M.C.L.I. British Society for Antimicrobial Chemotherapy CADIME-Camara De Instituciones De Diagnostico Medico Canadian Society for Medical Laboratory Science-Société Canadienne de Science de Laboratoire Médical Clinical Laboratory Management Association COLA College of American Pathologists

College of Medical Laboratory Technologists of Ontario College of Physicians and Surgeons of Saskatchewan **ESCMID** Fundación Bioquímica Argentina International Association of Medical Laboratory Technologists International Council for Standardization in Haematology International Federation of Clinical Chemistry Italian Society of Clinical Biochemistry and Clinical Molecular Biology Japan Society of Clinical Chemistry Japanese Committee for Clinical Laboratory Standards Joint Commission on Accreditation of Healthcare Organizations National Academy of Clinical Biochemistry National Association of Testing Authorities – Australia National Society for Histotechnology, Inc. Ontario Medical Association Quality Management Program-Laboratory Service **RCPA** Quality Assurance Programs PTY Limited Sociedade Brasileira de Analises Clinicas Sociedade Brasileira de Patologia Clinica Sociedad Espanola de Bioquimica Clinica y Patologia Molecular Turkish Society of Microbiology

#### **Government Members**

Association of Public Health Laboratories Armed Forces Institute of Pathology BC Centre for Disease Control Centers for Disease Control and Prevention Centers for Medicare & Medicaid Services/CLIA Program Centers for Medicare & Medicaid Services Chinese Committee for Clinical Laboratory Standards Commonwealth of Pennsylvania Bureau of Laboratories Department of Veterans Affairs Deutsches Institut für Normung (DIN) FDA Center for Devices and Radiological Health FDA Center for Veterinary Medicine FDA Division of Anti-Infective **Drug Products** Iowa State Hygienic Laboratory Massachusetts Department of Public Health Laboratories National Center of Infectious and Parasitic Diseases (Bulgaria) National Health Laboratory Service (South Africa) National Institute of Standards and Technology New York State Department of Health Ohio Department of Health Ontario Ministry of Health Pennsylvania Dept. of Health Saskatchewan Health-Provincial Laboratory Scientific Institute of Public Health; Belgium Ministry of Social Affairs, Public Health and the Environment Swedish Institute for Infectious Disease Control Thailand Department of Medical Sciences

#### **Industry Members**

AB Biodisk Abbott Laboratories Abbott Laboratories, MediSense Products Acrometrix Corporation Ammirati Regulatory Consulting Anaerobe Systems Asséssor AstraZeneca AstraZeneca R & D – Boston, MA Aventis Axis-Shield POC AS Bayer Corporation - Elkhart, IN Bayer Corporation - Tarrytown, NY Bayer Corporation - West Haven, CT Bayer Medical Ltd. BD BD Biosciences - San Jose, CA

#### Number 15

**BD** Consumer Products **BD** Diagnostic Systems BD Italia S.P.A. **BD VACUTAINER Systems** Beckman Coulter, Inc. Beckman Coulter, Inc. Primary Care Diagnostics Beckman Coulter K.K. (Japan) **Bio-Development SRL Bio-Inova Life Sciences** International **Bio-Inova Life Sciences North** America BioMedia Laboratories Sdn Bhd BioMérieux (NC) bioMérieux, Inc. (MO) **Biometrology Consultants** Bio-Rad Laboratories, Inc. Bio-Rad Laboratories, Inc. - France **Biotest AG** Blaine Healthcare Associates, Inc. Bristol-Myers Squibb Company Canadian External Quality Assessment Laboratory Capital Management Consulting, Inc. Carl Schaper Checkpoint Development Inc. Chiron Corporation ChromaVision Medical Systems, Inc. Chronolab Ag Clinical Design Group Inc. Clinical Laboratory Improvement Consultants Cognigen Community Medical Center (NJ) Control Lab (Brazil) Copan Diagnostics Inc. Cosmetic Ingredient Review **Cubist Pharmaceuticals** Dade Behring Inc. - Deerfield, IL Dade Behring Inc. - Glasgow, DE Dade Behring Inc. - Marburg, Germany Dade Behring Inc. - Sacramento, CA Dade Behring Inc. - San Jose, CA David G. Rhoads Associates, Inc. **Diagnostics Consultancy Diagnostic Products Corporation** Eiken Chemical Company, Ltd. Elan Pharmaceuticals Electa Lab s.r.l. Enterprise Analysis Corporation Essential Therapeutics, Inc. EXPERTech Associates, Inc. F. Hoffman-La Roche AG Fort Dodge Animal Health

General Hospital Vienna (Austria) Gen-Probe GlaxoSmithKline Greiner Bio-One Inc. Helena Laboratories Home Diagnostics, Inc. Immunicon Corporation Instrumentation Laboratory International Technidyne Corporation IntraBiotics Pharmaceuticals, Inc. **I-STAT** Corporation Johnson and Johnson Pharmaceutical Research and Development, L.L.C. Kendall Sherwood-Davis & Geck LAB-Interlink, Inc. Laboratory Specialists, Inc. Labtest Diagnostica S.A. LifeScan, Inc. (a Johnson & Johnson Company) Lilly Research Laboratories Macemon Consultants Medical Device Consultants, Inc. Merck & Company, Inc. Minigrip/Zip-Pak Molecular Diagnostics, Inc. mvi Sciences (MA) Nabi Nichols Institute Diagnostics (Div. of Quest Diagnostics, Inc.) NimbleGen Systems, Inc. Nissui Pharmaceutical Co., Ltd. Nippon Becton Dickinson Co., Ltd. Norfolk Associates, Inc. Novartis Pharmaceuticals Corporation Ortho-Clinical Diagnostics, Inc. (Raritan, NJ) Ortho-Clinical Diagnostics, Inc. (Rochester, NY) Oxoid Inc. Paratek Pharmaceuticals Pfizer Inc Pharmacia Corporation Philips Medical Systems Powers Consulting Services Premier Inc. Procter & Gamble Pharmaceuticals, Inc. The Product Development Group **QSE** Consulting Quintiles, Inc. Radiometer America, Inc. Radiometer Medical A/S Roche Diagnostics GmbH Roche Diagnostics, Inc.

Roche Laboratories (Div. Hoffmann-La Roche Inc.) Sarstedt, Inc. SARL Laboratoire Carron (France) Schering Corporation Schleicher & Schuell, Inc. Second Opinion Showa Yakuhin Kako Company, Ltd. Streck Laboratories, Inc. SurroMed, Inc. Synermed Diagnostic Corp. Sysmex Corporation (Japan) Sysmex Corporation - Long Grove, IL The Clinical Microbiology Institute The Toledo Hospital (OH) Theravance Inc. Transasia Engineers Trek Diagnostic Systems, Inc. Versicor, Inc. Vetoquinol S.A. Visible Genetics, Inc. Vysis, Inc. Wallac Oy Wyeth-Ayerst Xyletech Systems, Inc. **YD** Consultant YD Diagnostics (Seoul, Korea)

#### **Trade Associations**

AdvaMed Association of Medical Diagnostic Manufacturers Japan Association Clinical Reagents Ind. - Tokyo, Japan Medical Industry Association of Australia

#### **Associate Active Members**

20<sup>th</sup> Medical Group (SC) 31<sup>st</sup> Medical Group/SGSL (APO, AE) 67<sup>th</sup> CSH Wuerzburg, GE (NY) 121<sup>st</sup> General Hospital (CA) Academisch Ziekenhuis-VUB (Belgium) Acadiana Medical Laboratories, LTD (LA) Adena Regional Medical Center (OH)Advocate Healthcare Lutheran General (IL) Akershus Central Hospital and AFA (Norway) Albemarle Hospital (NC)

Volume 22

Allegheny General Hospital (PA) Allegheny University of the Health Sciences (PA) Allina Health System (MN) Alton Ochsner Medical Foundation (LA) American Medical Laboratories (VA) Antwerp University Hospital (Belgium) Arkansas Department of Health ARUP at University Hospital (UT) Armed Forces Research Institute of Medical Science (APO, AP) Associated Regional & University Pathologists (UT) Aurora Consolidated Laboratories (WI) Azienda Ospedale Di Lecco (Italy) Bay Medical Center (MI) Baystate Medical Center (MA) **Bbaguas Duzen Laboratories** (Turkey) Bermuda Hospitals Board Bo Ali Hospital (Iran) British Columbia Cancer Agency (Vancouver, BC, Canada) Brooks Air Force Base (TX) Broward General Medical Center (FL) Calgary Laboratory Services Carilion Consolidated Laboratory (VA) Cathay General Hospital (Taiwan) **CB** Healthcare Complex (Sydney, NS, Canada) Central Peninsula General Hospital (AK) Central Texas Veterans Health Care System Centre Hospitalier Regional del la Citadelle (Belgium) Centro Diagnostico Italiano (Milano, Italy) **Champlain Valley Physicians** Hospital (NY) Chang Gung Memorial Hospital (Taiwan) Changi General Hospital (Singapore) Children's Hospital (NE) Children's Hospital & Clinics (MN) Children's Hospital Medical Center (Akron, OH) Children's Hospital of Philadelphia (PA) Children's Medical Center of Dallas (TX)

Clarian Health-Methodist Hospital (IN)Clendo Lab (Puerto Rico) Clinical Laboratory Partners, LLC (CT) CLSI Laboratories (PA) Columbia Regional Hospital (MO) Commonwealth of Kentucky Community Hospital of Lancaster (PA) CompuNet Clinical Laboratories (OH)Cook County Hospital (IL) Cook Children's Medical Center (TX) Covance Central Laboratory Services (IN) Danish Veterinary Laboratory (Denmark) Danville Regional Medical Center (VA) Delaware Public Health Laboratory Department of Health & Community Services (New Brunswick, Canada) DesPeres Hospital (MO) DeTar Hospital (TX) Detroit Health Department (MI) Diagnosticos da América S/A (Brazil) Dr. Everett Chalmers Hospital (New Brunswick, Canada) Doctors Hospital (Bahamas) Duke University Medical Center (NC) E.A. Conway Medical Center (LA) Eastern Maine Medical Center East Side Clinical Laboratory (RI) Eastern Health (Vic., Australia) Elyria Memorial Hospital (OH) Emory University Hospital (GA) Esoterix Center for Infectious Disease (TX) Fairview-University Medical Center (MN) Federal Medical Center (MN) Florida Hospital East Orlando Foothills Hospital (Calgary, AB, Canada) Fort St. John General Hospital (Fort St. John, BC, Canada) Fox Chase Cancer Center (PA) Fresenius Medical Care/Spectra East (NJ) Fresno Community Hospital and Medical Center Frye Regional Medical Center (NC) Gambro Healthcare Laboratory Services (FL)

Gateway Medical Center (TN) Geisinger Medical Center (PA) Grady Memorial Hospital (GA) Guthrie Clinic Laboratories (PA) Hahnemann University Hospital (PA) Harris Methodist Erath County (TX) Harris Methodist Fort Worth (TX) Hartford Hospital (CT) Headwaters Health Authority (Alberta, Canada) Health Network Lab (PA) Health Partners Laboratories (VA) Heartland Regional Medical Center (MO) Highlands Regional Medical Center (FL) Hoag Memorial Hospital Presbyterian (CA) Holmes Regional Medical Center (FL) Holzer Medical Center (OH) Hopital du Sacre-Coeur de Montreal (Montreal, Quebec, Canada) Hôpital Maisonneuve – Rosemont (Montreal, Canada) Hospital for Sick Children (Toronto, ON, Canada) Hospital Sousa Martins (Portugal) Hotel Dieu Hospital (Windsor, ON, Canada) Houston Medical Center (GA) Huddinge University Hospital (Sweden) Hurley Medical Center (MI) Indiana State Board of Health Indiana University Institute of Medical and Veterinary Science (Australia) International Health Management Associates, Inc. (IL) Jackson Memorial Hospital (FL) Jersey Shore Medical Center (NJ) John C. Lincoln Hospital (AZ) John F. Kennedy Medical Center (NJ) John Peter Smith Hospital (TX) Kadlec Medical Center (WA) Kaiser Permanente Medical Care (CA) Kaiser Permanente (MD) Kantonsspital (Switzerland) Keller Army Community Hospital (NY) Kenora-Rainy River Regional Laboratory Program (Ontario, Canada) Kern Medical Center (CA)

M27-A2

Number 15

Kimball Medical Center (NJ) King Faisal Specialist Hospital (Saudi Arabia) King Khalid National Guard Hospital (Saudi Arabia) King's Daughter Medical Center (KY) Klinični Center (Slovenia) Laboratories at Bonfils (CO) Laboratoire de Santé Publique du Ouebec (Canada) Laboratório Fleury S/C Ltda. (Brazil) Laboratory Corporation of America (NJ) Laboratory Corporation of America (MO) LAC and USC Healthcare Network (CA) Lakeland Regional Medical Center (FL) Lancaster General Hospital (PA) Langley Air Force Base (VA) LeBonheur Children's Medical Center (TN) L'Hotel-Dieu de Quebec (Canada) Libero Instituto Univ. Campus BioMedico (Italy) Louisiana State University Medical Center Maccabi Medical Care and Health Fund (Israel) Magee Womens Hospital (PA) Malcolm Grow USAF Medical Center (MD) Manitoba Health (Winnipeg, Canada) Martin Luther King/Drew Medical Center (CA) Massachusetts General Hospital (Microbiology Laboratory) MDS Metro Laboratory Services (Burnaby, BC, Canada) Medical College of Virginia Hospital Medicare/Medicaid Certification, State of North Carolina Memorial Medical Center (IL) Memorial Medical Center (LA) Jefferson Davis Hwy Memorial Medical Center (LA) Napoleon Avenue Methodist Hospital (TX) Methodist Hospitals of Memphis (TN) MetroHealth Medical Center (OH) Michigan Department of Community Health

Mississippi Baptist Medical Center Monte Tabor - Centro Italo -Brazileiro de Promocao (Brazil) Montreal Children's Hospital (Canada) Montreal General Hospital (Canada) MRL Pharmaceutical Services, Inc. (VA) MRL Reference Laboratory (CA) Nassau County Medical Center (NY) National Institutes of Health (MD) Naval Hospital - Corpus Christi (TX) Naval Surface Warfare Center (IN) Nebraska Health System New Britain General Hospital (CT) New England Fertility Institute (CT) New Mexico VA Health Care Systems North Carolina State Laboratory of Public Health North Kansas City Hospital (MO) North Shore - Long Island Jewish Health System Laboratories (NY) Northwestern Memorial Hospital (IL) O.L. Vrouwziekenhuis (Belgium) Ordre professionnel des technologists médicaux du Ouébec Ospedali Riuniti (Italy) The Ottawa Hospital (Ottawa, ON, Canada) Our Lady of Lourdes Hospital (NJ) Our Lady of the Resurrection Medical Center (IL) Pathology and Cytology Laboratories, Inc. (KY) The Permanente Medical Group (CA) Piedmont Hospital (GA) Pikeville Methodist Hospital (KY) Pocono Hospital (PA) Presbyterian Hospital of Dallas (TX) Queen Elizabeth Hospital (Prince Edward Island, Canada) Queensland Health Pathology Services (Australia) Quest Diagnostics Incorporated (CA) Quintiles Laboratories, Ltd. (GA) **Regions Hospital** Reid Hospital & Health Care Services (IN)

Research Medical Center (MO) Rex Healthcare (NC) Rhode Island Department of Health Laboratories **Rivadh Armed Forces Hospital** (Saudi Arabia) Royal Columbian Hospital (New Westminster, BC, Canada) Sacred Heart Hospital (MD) Saint Mary's Regional Medical Center (NV) St. Alexius Medical Center (ND) St. Anthony Hospital (CO) St. Anthony's Hospital (FL) St. Barnabas Medical Center (NJ) St-Eustache Hospital (Quebec, Canada) St. Francis Medical Ctr. (CA) St. John Hospital and Medical Center (MI) St. John Regional Hospital (St. John, NB, Canada) St. Joseph Hospital (NE) St. Joseph's Hospital - Marshfield Clinic (WI) St. Joseph Mercy Hospital (MI) St. Jude Children's Research Hospital (TN) St. Luke's Regional Medical Center (IA) St. Mary of the Plains Hospital (TX) St. Mary's Hospital & Medical Center (CO) St. Paul's Hospital (Vancouver, BC, Montreal) St. Vincent Medical Center (CA) Ste. Justine Hospital (Montreal, PQ, Canada) Salina Regional Health Center (KS) San Francisco General Hospital (CA) Santa Clara Valley Medical Center (CA) Seoul Nat'l University Hospital (Korea) Shanghai Center for the Clinical Laboratory (China) South Bend Medical Foundation (IN)Southwest Texas Methodist Hospital (TX) South Western Area Pathology Service (Australia) Southern Maine Medical Center Specialty Laboratories, Inc. (CA) Stanford Hospital and Clinics (CA)

NCCLS

#### Volume 22

M27-A2

State of Washington Department of Health Stony Brook University Hospital (NY) Stormont-Vail Regional Medical Center (KS) Sun Health-Boswell Hospital (AZ) Sunrise Hospital and Medical Center (NV) Swedish Medical Center -Providence Campus (WA) Tampa General Hospital (FL) Temple University Hospital (PA) Tenet Odessa Regional Hospital (TX) The Toledo Hospital (OH) Touro Infirmary (LA) Trident Regional Medical Center (SC) Tripler Army Medical Center (HI) Truman Medical Center (MO) UCSF Medical Center (CA) UNC Hospitals (NC) University College Hospital (Galway, Ireland) University Hospital (Gent) (Belgium)

#### **OFFICERS**

Donna M. Meyer, Ph.D., President CHRISTUS Health

Thomas L. Hearn, Ph.D., President Elect Centers for Disease Control and Prevention

Emil Voelkert, Ph.D., Secretary Roche Diagnostics GmbH

Gerald A. Hoeltge, M.D., Treasurer The Cleveland Clinic Foundation

F. Alan Andersen, Ph.D., Immediate Past President Cosmetic Ingredient Review

John V. Bergen, Ph.D., Executive Director University Hospitals of Cleveland (OH)The University Hospitals (OK) University of Alabama-Birmingham Hospital University of Alberta Hospitals (Canada) University of Colorado Health Science Center University of Chicago Hospitals (IL) University of Illinois Medical Center University of the Ryukyus (Japan) University of Texas M.D. Anderson Cancer Center University of Virginia Medical Center University of Washington UZ-KUL Medical Center (Belgium) VA (Denver) Medical Center (CO) Virginia Department of Health VA (Kansas City) Medical Center (MO) VA (Western NY) Healthcare System VA (San Diego) Medical Center (CA)

VA (Tuskegee) Medical Center (AL) VA Outpatient Clinic (OH) Veile Hospital (Denmark) Washington Adventist Hospital (MD)Washoe Medical Center Laboratory (NV) West Jefferson Medical Center (LA)West Shore Medical Center (MI) Wilford Hall Medical Center (TX) William Beaumont Army Medical Center (TX) William Beaumont Hospital (MI) Williamsburg Community Hospital (VA) Winn Army Community Hospital (GA) Winnipeg Regional Health Authority (Winnipeg, Canada) Wishard Memorial Hospital (IN) Yonsei University College of Medicine (Korea) York Hospital (PA)

#### **BOARD OF DIRECTORS**

Susan Blonshine, RRT, RPFT, FAARC TechEd

Wayne Brinster BD

Kurt H. Davis, FCSMLS, CAE Canadian Society for Medical Laboratory Science

Lillian J. Gill, M.S. FDA Center for Devices and Radiological Health

Robert L. Habig, Ph.D. Habig Consulting Group

Carolyn D. Jones, J.D., M.P.H. AdvaMed Tadashi Kawai, M.D., Ph.D. International Clinical Pathology Center

J. Stephen Kroger, M.D., FACP COLA

Willie E. May, Ph.D National Institute of Standards and Technology

Gary L. Myers, Ph.D. Centers for Disease Control and Prevention

Barbara G. Painter, Ph.D. Bayer Corporation (Retired)

Judith A. Yost, M.A., M.T.(ASCP) Centers for Medicare & Medicaid Services

Number 15

Volume 22	M27-A2

# Contents

Abstra			i
		embership	
		•	
		ership	
Forew	ord		.XV
The Q	uality S	ystem Approach	xvi
1	Introd	uction	1
	1.1 1.2	Scope Definitions	
2	Antifu	ingal Agents	2
	2.1 2.2 2.3 2.4 2.5	Source Weighing Antifungal Powders Preparing Stock Solutions Number of Concentrations Tested Selection of Antifungal Agents for Routine Testing and Reporting	2 3 4
3	Test P	Procedures	4
	3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 3.10	Broth Medium Preparing Diluted Antifungal Agents Inoculum Preparation Inoculating RPMI-1640 Medium Incubation Reading Results Interpretation of Results Broth Microdilution Modifications Impact of Time Reading: 24 Hours versus 48 Hours Other Modifications	5 6 6 6 7 8 9
4	Qualit	y Control	9
	4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9	Purpose Quality Control Responsibilities Selecting Reference Strains Storing Reference Strains Routine Use of Reference Strains Batch of Medium and Lot of Plasticware Control Quality Control Frequency Other Control Procedures Quality Control Strains	10 10 11 12 12 12 12
Refere		~	
Appen	ndix A. I	RPMI 1640 Medium	.18
Appen	dix B.	McFarland 0.5 Barium Sulfate Turbidity Standard	
Appen	dix C.	Interpretive Guidelines for In Vitro Susceptibility Testing of Candida Species	19

Number 15	NCCLS

# **Contents (Continued)**

Table 1.      Solvents and Diluents for Preparation of Stock Solutions of Antifungal Agents      20
Table 2. Scheme for Preparing Dilutions of Water-Soluble Antifungal Agents to Be Used      in Broth Dilution Susceptibility Tests
Table 3. Scheme for Preparing Dilution Series of Water-Insoluble Antifungal Agents to      Be Used in Broth Dilution Susceptibility Tests
Table 4. Recommended 48-hour MIC Limits for Two Quality Control and Four Reference Strains for Broth Macrodilution Procedures.    22
Table 5. Recommended 24- and 48-hour MIC Limits for Two Quality Control Strains   for Broth Microdilution.
Table 6. Composition of RPMI 1640 Medium (with glutamine and phenol red but without bicarbonate)    24
Table 7. Modifications for Special Circumstances 25
Summary of Comments and Subcommittee Responses
Summary of Delegate Comments and Subcommittee Responses
Related NCCLS Publications

Volume 22

### Foreword

With the increased incidence of systemic fungal infections and the growing number of antifungal agents, laboratory aids to guide in the selection of antifungal therapy have gained greater attention. In 1982, the NCCLS Area Committee for Microbiology formed the Subcommittee on Antifungal Susceptibility Testing. In 1985, this subcommittee published its first report<sup>1</sup> in which the results of a questionnaire and a small collaborative study were presented. These results are summarized as follows:

- Approximately 20% of the responding NCCLS membership whose hospitals had greater than 200 beds were performing antifungal testing.
- Most testing involved broth dilution methodology.
- Most strains tested were *Candida albicans* or other species of yeasts.
- Most centers tested only a few isolates per year.
- Agreement in minimal inhibitory concentration (MIC) results among several laboratories that participated in a collaborative study was unacceptably low.

Based on these findings, the subcommittee concluded that it would be useful to work toward a more reproducible reference testing procedure.

Agreement already existed regarding several elements of the procedure. To facilitate further analysis of various test conditions, the reference method should be a broth macrodilution procedure. Because of examples of drug antagonism by some complex media for certain antifungals, the subcommittee restricted its interest only to fully defined synthetic media. Drug stock solution preparation and dilution procedures previously developed for antibacterial testing procedures were adopted with minor modifications.

Despite agreement in some areas, other factors required additional data to be resolved. These included inoculum preparation; inoculum size; choice among several synthetic media; temperature of incubation; duration of incubation; and end-point definition. These factors were the focus of a series of collaborative studies.<sup>2,3,4,5</sup> As a result; agreement within the subcommittee was achieved on all of the factors and led to the publication of M27-P in 1992. In the next four years (1992-1996), reference MIC ranges were established for two quality control strains for the available antifungal agents,<sup>6,7</sup> and broth microdilution procedures paralleling the broth macrodilution reference procedure became available.<sup>5,8,9,10</sup> This information was included in a revised standard in 1995 (M27-T). In further revising the document, the subcommittee focused its attention on developing relevant breakpoints for available antifungal agents,<sup>11</sup> included in M27-A (1997). Since then the subcommittee has developed 24- and 48-hour reference MIC ranges for microdilution testing of both established and newly introduced antifungal agents.<sup>12</sup> The results of these studies are included in the current M27-A2 document.

#### **Standard Precautions**

Because it is often impossible to know what might be infectious, all human blood specimens are to be treated as infectious and handled according to "standard precautions." Standard precautions are new guidelines that combine the major features of "universal precautions and body substance isolation" practices. Standard precautions cover the transmission of any pathogen and thus are more comprehensive than universal precautions which are intended to apply only to transmission of blood-borne pathogens. Standard precaution and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (*Guideline for Isolation Precautions in Hospitals*. Infection Control and Hospital Epidemiology. CDC. 1996;Vol 17;1:53-80), (MMWR 1987;36[suppl 2S]2S-18S), and (MMWR

#### Number 15

NCCLS

1988;37:377-382, 387-388). For specific precautions for preventing the laboratory transmission of bloodborne infection from laboratory instruments and materials and for recommendations for the management of blood-borne exposure, refer to the most current edition of NCCLS document M29—*Protection of Laboratory Workers from Occupationally Acquired Infections*.

#### **Key Words**

Antifungal, broth macrodilution, broth microdilution, susceptibility testing, yeasts

## The Quality System Approach

NCCLS subscribes to a quality system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents through a gap analysis. The approach is based on the model presented in the most current edition of NCCLS HS1—*A Quality System Model for Health Care.* The quality system approach applies a core set of "quality system essentials (QSEs)," basic to any organization, to all operations in any healthcare service's path of workflow. The QSEs provide the framework for delivery of any type of product or service, serving as a manager's guide. The quality system essentials (QSEs) are:

QSEs						
Documents & Records	Information Management					
Organization	Occurrence Management					
Personnel	Assessment					
Equipment	Process Improvement					
Purchasing & Inventory	Service & Satisfaction					
Process Control	Facilities & Safety					

#### M27-A2 Addresses the Following Quality System Essentials (QSEs):

Documents & Records	Organization	Personnel	Equipment	Purchasing & Inventory	X Control	Information Management	Occurrence Management	Assessment	Process Improvement	Service & Satisfaction	Facilities & Safety	
------------------------	--------------	-----------	-----------	---------------------------	--------------	---------------------------	--------------------------	------------	------------------------	---------------------------	------------------------	--


Adapted from NCCLS document HS1—A Quality System Model for Health Care

Volume 22

M27-A2

#### Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, GP26-A2 defines a clinical laboratory path of workflow which consists of three sequential processes: preanalytical, analytical, and postanalytical. All clinical laboratories follow these processes to deliver the laboratory's services, namely quality laboratory information. The arrow depicts the sequence, from left to right, that any clinical laboratory follows. In addition, the necessary steps or subprocesses are listed below them.



Adapted from NCCLS document HS1-A—A Quality System Model for Health Care

Most of NCCLS's documents relate to the clinical laboratory, so the most common path of workflow will be that depicted above. The path of workflow for other healthcare activities, e.g., respiratory services, imaging services, etc., or for other types of organizations, e.g., medical device manufacturers, will differ from that of the clinical laboratory. All such paths of workflow describe the sequence of activities necessary to produce the organization's or an entity's specific product or services. For those documents that relate to other paths of workflow, the icon will reflect different process steps.

Preanalytical				Analytical		Postanalytical		
Patient	Test	Specimen	Specimen	Specimen	Testing	Laboratory	Results	Post-test
Assessment	Request	Collection	Transport	Receipt	Review	Interpre-	Report	Specimen
						tation		Management
					Х	Х	Х	Х

Number 15

Volume 22

M27-A2

# Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition

# **1** Introduction

The method described in this document is intended for testing yeasts that cause invasive infections. These yeasts encompass *Candida* species (including *Candida* glabrata) and *Cryptococcus neoformans*. The method has not been used in studies of the yeast form of dimorphic fungi, such as *Blastomyces dermatitidis* or *Histoplasma capsulatum* variety *capsulatum*. Moreover, testing filamentous fungi (moulds) introduces several additional problems in standardization not addressed by the current procedure. A reference method for broth dilution antifungal susceptibility testing of filamentous fungi has been developed and is now available as NCCLS document M38—*Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi*.<sup>13,14</sup>

M27-A2 is a "reference" standard being developed through a consensus process to facilitate the agreement among laboratories in measuring the susceptibility of yeasts to antifungal agents. An important use of a reference method is to provide a standard basis from which other methods can be developed, which also will result in interlaboratory agreement within specified ranges. For example, broth microdilution methods, described in this document, have been configured to produce results paralleling those obtained by the reference method. Such methods might have particular advantages, such as ease of performance, economy, or more rapid results; therefore, their development could be highly desirable. To the extent that any method produces concordant results with this reference method, it would be considered to be in conformity with M27-A2.

### 1.1 Scope

This document describes a method for testing the susceptibility to antifungal agents of yeast that cause infections, including *Candida* species and *Cryptococcus neoformans*. This method has not been extensively validated in yeast form of dimorphic fungi, such as *Blastomyces dermatitidis* or *Histoplasma capsulatum* variety *capsulatum*.

The subcommittee has focused on developing relevant breakpoints for available antifungal agents,<sup>11</sup> and reference MIC ranges for microdilution testing of both established and newly introduced antifungal agents.<sup>12</sup>

#### 1.2 Definitions<sup>a</sup>

Antibiogram, n – Overall profile of antimicrobial susceptibility results of a microbial species to a battery of antimicrobial agents.

**Minimal inhibitory concentration (MIC),** n – The lowest concentration of an antimicrobial agent that prevents visible growth of a microorganism in an agar or broth dilution susceptibility test.

<sup>&</sup>lt;sup>a</sup> Some of these definitions are found in NCCLS document NRSCL8—*Terminology and Definitions for Use in NCCLS Documents.* For complete definitions and detailed source information, please refer to the most current edition of that document.